Table 1.
Baseline characteristics
| Characteristic | No. (%) (n=360) |
|---|---|
| Age, median (range, yr) | 63 (23-88) |
| < 65 | 204 (56.7) |
| ≥ 65 | 156 (43.3) |
| Sex | |
| Female | 127 (35.3) |
| Male | 233 (64.7) |
| Location | |
| Colon/S-colon | 230 (63.9) |
| Rectum | 130 (36.1) |
| Histological type | |
| Well/Moderate differentiation | 304 (84.4) |
| Poor differentiation/Mucinous/Signet ring cell | 56 (15.6) |
| Metastatic presentation | |
| Metachronous | 128 (35.6) |
| Synchronous | 232 (64.4) |
| No. of metastatic organs | |
| Only one (1) | 204 (56.7) |
| More than one (≥ 2) | 156 (43.3) |
| First-line chemotherapy | |
| FOLFOX/FOLFIRI | 260 (72.2) |
| FOLFOX/FOLFIRI+targeting agent (bevacizumab or cetuximab) | 100 (27.8) |
| Initial CEA, median (range, ng/mL) | 24.62 (0.10-5,158.00) |
Values are presented as number (%). FOLFOX, oxaliplatin plus fluorouracil and leucovorin; FOLFIRI, cetuximab plus irinotecan, fluorouracil, and leucovorin; CEA, carcinoembryonic antigen.